Latest revenue
$24.6M
as of 2026-01-31
Latest net income
$-34.2M
as of 2026-01-31
Net margin
-139.2%
as of 2026-01-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.26B
- Enterprise value
- $1.26B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $30.00
- 52-wk low
- $13.25
- Beta
- —
- Shares out
- 58.4M
5-year trend
What this company does
Kestra Medical Technologies sells the ASSURE wearable cardioverter defibrillator, a vest-like device that monitors high-risk cardiac patients and delivers a shock to prevent sudden cardiac arrest. Revenue comes primarily from prescriptions of the ASSURE WCD and its connected Cardiac Recovery System platform, billed largely through Medicare and insurance reimbursement averaging roughly $3,500 per patient per month. Kestra is the first serious challenger to a 20-year monopoly in the $1.3 billion WCD market, competing on fewer false alarms, better comfort, and gender-specific garments.
Generated from KMTS's filing dated 2025-07-17
Key risks
- Single-product concentration: ASSURE WCD is essentially the entire business, leaving Kestra exposed to any clinical, regulatory, or recall setback.
- Direct competition with entrenched ZOLL LifeVest, which has held the WCD monopoly 20+ years; Kestra still reaches only minority share of $1.3B market.
- Reimbursement dependence: ~$3,519/month Medicare rate per patient drives the $10B TAM math—any CMS rate cut would materially impair revenue.
Generated from KMTS's filing dated 2025-07-17
Profitability
Gross margin
40.5%
3009.9%Operating margin
-177.8%
41.8%Net margin
-190.3%
43.8%Return on assets
-38.5%
81.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-01-31 | $24.6M | +62.7% | $-34.2M | -58.8% | -139.2% |
Q4 2025 2025-10-31 | $22.6M | +53.4% | $-32.8M | -61.0% | -145.3% |
Q3 2025 2025-07-31 | $19.4M | +51.5% | $-25.8M | -29.9% | -133.3% |
Q2 2025 2025-04-30 | $17.2M | — | $-52.1M | — | -302.1% |
Q1 2025 2025-01-31 | $15.1M | +82.3% | $-21.5M | +0.5% | -142.5% |
Q4 2024 2024-10-31 | $14.7M | — | $-20.4M | — | -138.5% |
Q3 2024 2024-07-31 | $12.8M | — | $-19.9M | — | -155.6% |
Q1 2024 2024-01-31 | $8.3M | — | $-21.6M | — | -261.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on KMTS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$199.8K
Insider selling
$2.3M
Net activity
−$2.1M
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns KMTS
Institutional value
$178.7M
Total shares held
9.0M
Distinct holders
55
-52 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | ANDERA PARTNERS | 2.7M | $53.7M | +155.1K (+6.1%) | Added |
| 2 | BlackRock, Inc. | 1.7M | $33.7M | +454.6K (+36.8%) | Added |
| 3 | FRANKLIN RESOURCES INC | 1.2M | $24.8M | +292.2K (+30.7%) | Added |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $24.2M | — | New |
| 5 | FEDERATED HERMES, INC. | 525.0K | $10.5M | +0 (+0.0%) | No change |
| 6 | UBS Group AG | 349.7K | $7.0M | +79.6K (+29.5%) | Added |
| 7 | SEI INVESTMENTS CO | 237.1K | $4.7M | +43.8K (+22.6%) | Added |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 218.8K | $4.4M | — | New |
| 9 | VANGUARD FIDUCIARY TRUST CO | 145.7K | $2.9M | — | New |
| 10 | TD ASSET MANAGEMENT INC | 109.4K | $2.2M | -23.5K (-17.7%) | Trimmed |
| 11 | SEVEN GRAND MANAGERS, LLC | 100.0K | $2.0M | +0 (+0.0%) | No change |
| 12 | Bank of New York Mellon Corp | 70.1K | $1.4M | +22.5K (+47.2%) | Added |
| 13 | Swiss National Bank | 39.6K | $789.2K | +0 (+0.0%) | No change |
| 14 | Nuveen, LLC | 31.9K | $635.3K | +8.4K (+35.9%) | Added |
| 15 | Spartan Wealth Advisory Services LLC | 30.3K | $603.2K | — | New |
| 16 | DEUTSCHE BANK AG\ | 29.3K | $583.1K | +11.4K (+63.6%) | Added |
| 17 | RHUMBLINE ADVISERS | 26.3K | $524.9K | +10.6K (+67.2%) | Added |
| 18 | NEW YORK STATE COMMON RETIREMENT FUND | 25.1K | $499.8K | +0 (+0.0%) | No change |
| 19 | JPMORGAN CHASE & CO | 25.8K | $472.7K | +6.0K (+30.3%) | Added |
| 20 | Mirae Asset Global Investments Co., Ltd. | 20.7K | $412.4K | +3.7K (+21.8%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
With ZOLL's LifeVest entrenched for 20+ years, what specific active-prescription and reorder metrics demonstrate ASSURE is taking share versus simply expanding the 14% penetrated market?
- 2
Given $3,519 Medicare reimbursement underpins your $10B TAM, what percentage of revenue is currently Medicare versus commercial, and are payers pushing back on rates?
- 3
ACE-PAS showed 23-hour median wear time, but what's your actual compliance-adjusted gross margin per patient after garment returns, service costs, and bad debt?
Refreshed when KMTS files a new report · last from 2025-07-17